Low-Dose Aspirin Reduced Risk of HCC in Patients With HBV or HCV
In a registry study, patients with HBV or HCV who began low-dose aspirin had lower rates of HCC and 10-year liver-related mortality compared with nonusers.
Hepatocellular Carcinoma
Risk for Liver Cancer Down With Low-Dose Aspirin in Hepatitis B, C
Risk for 10-year liver-related mortality also lower among aspirin users with chronic hepatitis B or C.
Tumor-Immune Interactions May Contribute to Intratumoral Heterogeneity in Hepatocellular Carcinoma
Information on ITH can provide insight into the clonal evolutionary processes occurring within the tumor in response to prior treatment.
Study Reveals Differences Between the Genomic Profiles of Primary Tumors and Metastatic Lesions in Intrahepatic Cholangiocarcinoma
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
Prior Exposure to Antibiotics or Antacids Did Not Reduce Immunotherapy Response in Advanced HCC
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
Tumor Size and Stiffness May Be Relevant Biomarkers of Response to ICIs in Hepatocellular Carcinoma
The median change in HCC tumor size between responders and nonresponders was statistically significant.
MET Gene Amplification Found to Be Associated With Adverse Clinicopathological Features in Gallbladder Cancer
In this study, there was no correlation between the presence of MET gene amplification and the presence of MET protein overexpression.
Microbiome-Derived Therapy Gets Orphan Drug Status for Hepatocellular Carcinoma
SFA001 blocked the progression of hepatitis B to HCC in transgenic HBX animal models
PHGDH Identified as a Potential Target to Overcome Sorafenib Resistance in HCC
PHGDH may be a possible target for overcoming sorafenib resistance, preclinical evidence suggests.
Next post in Gastrointestinal Cancers
